ArticleFrontiers in pharmacology2026
Exploratory pharmacokinetic/pharmacodynamic range of tigecycline for balancing treatment effect and safety in hospital-acquired pneumonia: a retrospective cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tigecycline (TGC) is a core antibiotic for treating hospital-acquired pneumonia (HAP) caused by multidrug-resistant (MDR) bacteria, but the absence of individualized dosing guidance that balances treatment effect and safety frequently results in suboptimal efficacy or coagulation-related adverse events in clinical practice. Methods: A single-center retrospective study was conducted, enrolling 100 patients with MDR-HAP who were assigned to a standard-dose group or a high-dose group based on clinical decisions. The efficacy and safety of different TGC dosing regimens were compared between the two groups. Results: The trough concentration (C Discussion: This eAUIC range was derived from retrospective data and should be framed explicitly as a hypothesis to be tested, clinical applicability requires confirmation through prospective studies and external validation. Therapeutic drug monitoring may assist in optimizing therapy, but prospective studies are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.